OncoMatch/Clinical Trials/NCT06205472
Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.
Is NCT06205472 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for hepatocellular carcinoma.
This is a single-arm prospective phase II clinical trial to investigate the efficacy and safety of adjuvant simultaneouslyintegrated boost radiotherapy following narrow-margin(\<1cm) hepatectomy in patients with HCC. Eligibility patients will receive IMRT or VMAT to high risk area of tumor bed and tumor bed. The prescription dose to 95% GTVtb boost was planned at 55-60Gy, with PTV 45-50Gy, in 23-25 fractions, mainly depending on the dose constraints of OARs. The primary endpoint is the 3-year OS, the secondary endpoints are disease-free survival, patterns of failure, toxic events and local control rate.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Excluded: Stage DISTANT METASTASIS (M1)
No distant metastasis (M0)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: hepatectomy
Pathological diagnosis of HCC after hepatectomy with narrow pathological margins (< 1 cm)
Cannot have received: abdominal irradiation
Had prior abdominal irradiation
Cannot have received: liver transplantation
Had prior liver transplantation
Lab requirements
Blood counts
Hb≥80g/L, ANC≥1.0x10^9/L, PLT≥50x10^9/L
Kidney function
creatinine(CRE) and blood urea nitrogen(BUN)≤1.5 times ULN
Liver function
alanine transaminase(ALT) and aspartate transaminase(AST) ≤1.5 times ULN; or ALT ≤ULN and AST ≤6 times ULN exclude possibility of heart disease; Child-Push Score: A5-A6
Blood routine examination: Hb≥80g/L, ANC≥1.0x10^9/L, PLT≥50x10^9/L; Hepatic function: alanine transaminase(ALT) and aspartate transaminase(AST) ≤1.5 times ULN; or ALT ≤ULN and AST ≤6 times ULN exclude possibility of heart disease; Child-Push Score: A5-A6; Renal function: creatinine(CRE) and blood urea nitrogen(BUN)≤1.5 times ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06205472 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior abdominal irradiation, liver transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages